피부 및 전신성 리슈마니아증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 약물 종류별, 투여 경로별, 적응증별, 유통 채널별, 지역별

Cutaneous and Systemic Leishmaniasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 6,864,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,673,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,566,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전 세계 피부 및 전신성 리슈마니아증 시장 규모는 예측 기간인 2024년부터 2031년까지 상승세를 보일 것으로 예상됩니다. 이러한 성장은 시장 확대를 주도하는 몇 가지 주요 요인에 기인하는 것으로 보입니다.

피부 및 전신성 리슈마니아증 시장의 성장을 촉진하는 매우 중요한 요인 중 하나는 병용 약물 요법을 통해 달성되는 인상적인 임상 치료율입니다. 다양한 약물의 조합은 매우 효과적임이 입증되었으며, 일부 조합은 완전한 완치에 이르는 것으로 입증되었습니다. 이러한 유망한 측면은 예측 기간 동안 시장 성장을 유지할 것으로 예상됩니다.

피부 및 전신성 리슈마니아증 시장의 많은 이해관계자들은 혁신적인 치료법을 개발하기 위해 연구개발에 많은 투자를 하고 있습니다. 현재 진행 중인 다양한 약물 및 치료법에 대한 임상시험은 유망한 결과를 보여주고 있으며, 피부 및 전신성 리슈마니아증 치료의 새로운 가능성을 열어줄 것으로 기대되고 있습니다.

세계 각국 정부는 의료 인프라에 많은 투자를 하고 있으며, 이는 시장 성장에 기여하고 있습니다. 또한, 민간 의료 보험 제공자가 유리한 상환 정책을 제공함에 따라 환자는 자신의 필요에 가장 적합한 플랜을 선택할 수 있어 치료에 대한 접근이 더욱 쉬워지고 있습니다.

피부 및 전신성 리슈마니아증의 치료비용은 여전히 고가의 약품으로 인해 상대적으로 높은 편이며, 이러한 치료법은 심각한 부작용을 초래할 수 있습니다. 하지만 현재 진행 중인 연구 개발 노력으로 인해 향후 더 비용 효율적이고 안전한 치료법이 개발될 것으로 기대됩니다.

피부 및 전신성 리슈마니아증 시장은 경쟁이 치열하며, 주요 기업들이 시장을 지배하고 있는 것이 특징입니다. 시장 진입 기업들은 증가하는 수요에 대응하고 지역 시장에서 우위를 점하기 위해 기술 제휴, 대리점 계약, 연구 개발 강화, 제품 출시 등 새롭고 혁신적인 전략을 도입하고 있습니다.

이 보고서는 세계 피부 및 전신성 레슈마니아증 시장에 대해 조사했으며, 시장 개요와 함께 약품 종류별, 투여 경로별, 적응증별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

• 세계의 피부 및 전신성 리슈마니아증 시장 전망, 약제 클래스별, 금액(10억 달러), 2018-2031년
• 세계의 피부 및 전신성 리슈마니아증 시장 전망, 투여 경로별, 금액(10억 달러), 2018-2031년
• 세계의 피부 및 전신성 리슈마니아증 시장 전망, 적응증별, 금액(10억 달러), 2018-2031년
• 세계의 피부 및 전신성 리슈마니아증 시장 전망, 유통 채널별, 금액(달러), 2018-2031년
• 세계의 피부 및 전신성 리슈마니아증 시장 전망, 지역별, 금액(10억 달러), 2018-2031년

제4장 북미의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

제5장 유럽의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

제6장 아시아태평양의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

제7장 라틴아메리카의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 피부 및 전신성 리슈마니아증 시장 전망, 2018-2031년

제9장 경쟁 상황

• 약제 클래스와 적응증 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁 대시보드
• 기업 개요
  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

제10장 부록

ksm

영문 목차

영문목차

The global Cutaneous and Systemic Leishmaniasis market is on an upward trajectory over the forecast period 2024-2031. This growth can be attributed to several key factors that are driving the market's expansion.

High Clinical Cure Rate with Combinational Drug Therapy

One of the pivotal factors fueling the growth of the Cutaneous and Systemic Leishmaniasis market is the impressive clinical cure rate achieved through combinational drug therapy. The use of various drug combinations has proven to be highly effective, with some combinations even resulting in complete cures. This promising aspect is expected to sustain the market's growth throughout the forecast period.

Increased Investments for Research And Development

Numerous stakeholders in the Cutaneous and Systemic Leishmaniasis market are making substantial investments in research and development efforts aimed at developing innovative treatment alternatives. Ongoing clinical trials for a wide range of drugs and therapies show promising outcomes, which are anticipated to open up new opportunities for treating cutaneous and systemic leishmaniasis.

Favorable Reimbursement Policies

Governments worldwide are significantly investing in healthcare infrastructure, contributing to the growth of the market. Additionally, private health insurance providers are offering favorable reimbursement policies, allowing patients to choose plans that best suit their needs, further facilitating access to treatment.

However, the market does face some challenges:

High Cost of Treatment and Chances Of Side Effects

The cost of treating Cutaneous and Systemic Leishmaniasis remains relatively high due to expensive drugs, and these treatments may have serious side effects. Nevertheless, ongoing research and development efforts are expected to yield more cost-effective and safer treatment options in the future.

Impact of COVID-19

The COVID-19 pandemic initially led to a decrease in demand for Cutaneous & Systemic Leishmaniasis treatment due to healthcare facilities' overwhelming focus on managing the pandemic. However, as the situation improved in 2021, demand for these treatments started to rebound.

Competitive Analysis

The Cutaneous and Systemic Leishmaniasis market is fiercely competitive and is characterized by major players dominating the industry. Market participants are embracing new and innovative strategies, including technological collaborations, distributorship agreements, increased research and development, and product launches, to meet growing demand and establish their dominance in regional markets.

Key Companies Profiled

• Gilead Sciences, Inc.
• Profounda Pharmaceuticals
• Knight Therapeutics Inc.
• Janssen Global Services, LLC
• Albert David Ltd
• Jubilant Life Sciences Ltd.
• Novartis AG
• Sanofi
• Endo Pharmaceuticals Inc
• Bristol-Myers Squibb Company
• United Biotech Pvt. Ltd.

As the Cutaneous & Systemic Leishmaniasis market continues to grow and evolve, these key players are at the forefront of driving advancements in research, development, and access to treatment, ensuring a brighter future for those affected by this disease.

Cutaneous and Systemic Leishmaniasis Market Categorization

Cutaneous and Systemic Leishmaniasis Market by By Drug Class

• Pentavalent Antimonials
• Antifungal Drugs
• Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous and Systemic Leishmaniasis Market By Route of Administration

• Oral
• Injectable
• Topical

Cutaneous and Systemic Leishmaniasis Market By Indication

• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis
• Visceral Leishmaniasis

Cutaneous and Systemic Leishmaniasis Market By Distribution Channel

• Hospital Pharmacies,
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Cutaneous and Systemic Leishmaniasis Market by Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Cutaneous and Systemic Leishmaniasis Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 3.1. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Pentavalent Antimonials
    • 3.1.1.2. Antifungal Drugs
    • 3.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 3.2. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Oral
    • 3.2.1.2. Injectable
    • 3.2.1.3. Topical
• 3.3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Cutaneous Leishmaniasis
    • 3.3.1.2. Mucosal Leishmaniasis
    • 3.3.1.3. Visceral Leishmaniasis
• 3.4. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. Hospital Pharmacies,
    • 3.4.1.2. Retail Pharmacies
    • 3.4.1.3. Drug Stores
    • 3.4.1.4. Online Pharmacies
• 3.5. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.5.1. Key Highlights
    • 3.5.1.1. North America
    • 3.5.1.2. Europe
    • 3.5.1.3. Asia Pacific
    • 3.5.1.4. Latin America
    • 3.5.1.5. Middle East & Africa

4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 4.1. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Pentavalent Antimonials
    • 4.1.1.2. Antifungal Drugs
    • 4.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 4.2. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Oral
    • 4.2.1.2. Injectable
    • 4.2.1.3. Topical
• 4.3. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Cutaneous Leishmaniasis
    • 4.3.1.2. Mucosal Leishmaniasis
    • 4.3.1.3. Visceral Leishmaniasis
• 4.4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospital Pharmacies,
    • 4.4.1.2. Retail Pharmacies
    • 4.4.1.3. Drug Stores
    • 4.4.1.4. Online Pharmacies
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis
• 4.5. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.5.1. Key Highlights
    • 4.5.1.1. U.S. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.5.1.2. U.S. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.5.1.3. U.S. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.5.1.4. U.S. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.1.5. Canada Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.5.1.6. Canada Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.5.1.7. Canada Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.5.1.8. Canada Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 5.1. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Pentavalent Antimonials
    • 5.1.1.2. Antifungal Drugs
    • 5.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 5.2. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Oral
    • 5.2.1.2. Injectable
    • 5.2.1.3. Topical
• 5.3. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Cutaneous Leishmaniasis
    • 5.3.1.2. Mucosal Leishmaniasis
    • 5.3.1.3. Visceral Leishmaniasis
• 5.4. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospital Pharmacies,
    • 5.4.1.2. Retail Pharmacies
    • 5.4.1.3. Drug Stores
    • 5.4.1.4. Online Pharmacies
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis
• 5.5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.5.1. Key Highlights
    • 5.5.1.1. Germany Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.2. Germany Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.3. Germany Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.4. Germany Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.5. U.K. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.6. U.K. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.7. U.K. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.8. U.K. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.9. France Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.10. France Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.11. France Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.12. France Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.13. Italy Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.14. Italy Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.15. Italy Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.16. Italy Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.17. Turkey Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.18. Turkey Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.19. Turkey Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.20. Turkey Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.21. Russia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.22. Russia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.23. Russia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.24. Russia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1.25. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.5.1.26. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.5.1.27. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.5.1.28. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Pentavalent Antimonials
    • 6.1.1.2. Antifungal Drugs
    • 6.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 6.2. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Oral
    • 6.2.1.2. Injectable
    • 6.2.1.3. Topical
• 6.3. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Cutaneous Leishmaniasis
    • 6.3.1.2. Mucosal Leishmaniasis
    • 6.3.1.3. Visceral Leishmaniasis
• 6.4. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospital Pharmacies,
    • 6.4.1.2. Retail Pharmacies
    • 6.4.1.3. Drug Stores
    • 6.4.1.4. Online Pharmacies
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis
• 6.5. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.5.1. Key Highlights
    • 6.5.1.1. China Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.2. China Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.3. China Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.4. China Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.5. Japan Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.6. Japan Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.7. Japan Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.8. Japan Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.9. South Korea Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.10. South Korea Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.11. South Korea Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.12. South Korea Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.13. India Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.14. India Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.15. India Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.16. India Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.17. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.18. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.19. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.20. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1.21. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.5.1.22. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.5.1.23. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.5.1.24. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 7.1. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Pentavalent Antimonials
    • 7.1.1.2. Antifungal Drugs
    • 7.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 7.2. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Oral
    • 7.2.1.2. Injectable
    • 7.2.1.3. Topical
• 7.3. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Cutaneous Leishmaniasis
    • 7.3.1.2. Mucosal Leishmaniasis
    • 7.3.1.3. Visceral Leishmaniasis
• 7.4. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospital Pharmacies,
    • 7.4.1.2. Retail Pharmacies
    • 7.4.1.3. Drug Stores
    • 7.4.1.4. Online Pharmacies
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis
• 7.5. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.5.1. Key Highlights
    • 7.5.1.1. Brazil Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.5.1.2. Brazil Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.3. Brazil Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.4. Brazil Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.5. Mexico Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.5.1.6. Mexico Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.7. Mexico Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.8. Mexico Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.9. Argentina Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.5.1.10. Argentina Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.11. Argentina Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.12. Argentina Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1.13. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.5.1.14. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.5.1.15. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.5.1.16. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Pentavalent Antimonials
    • 8.1.1.2. Antifungal Drugs
    • 8.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
• 8.2. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Oral
    • 8.2.1.2. Injectable
    • 8.2.1.3. Topical
• 8.3. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Cutaneous Leishmaniasis
    • 8.3.1.2. Mucosal Leishmaniasis
    • 8.3.1.3. Visceral Leishmaniasis
• 8.4. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospital Pharmacies,
    • 8.4.1.2. Retail Pharmacies
    • 8.4.1.3. Drug Stores
    • 8.4.1.4. Online Pharmacies
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis
• 8.5. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.5.1. Key Highlights
    • 8.5.1.1. GCC Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.5.1.2. GCC Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.3. GCC Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.4. GCC Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.5. South Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.5.1.6. South Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.7. South Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.8. South Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.9. Egypt Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.5.1.10. Egypt Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.11. Egypt Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.12. Egypt Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.13. Nigeria Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.5.1.14. Nigeria Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.15. Nigeria Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.16. Nigeria Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1.17. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.5.1.18. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.5.1.19. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.5.1.20. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Drug Class vs Indication Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Gilead Sciences, Inc.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Profounda Pharmaceuticals
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Knight Therapeutics Inc.
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Janssen Global Services, LLC
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Albert David Ltd
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Jubilant Life Sciences Ltd.
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Novartis AG
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Sanofi
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. Endo Pharmaceuticals Inc
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Bristol-Myers Squibb Company
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development
  • 9.4.11. United Biotech Pvt. Ltd.
    • 9.4.11.1. Company Overview
    • 9.4.11.2. Product Portfolio
    • 9.4.11.3. Financial Overview
    • 9.4.11.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료